---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-020080"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-06-10T11:40:43+00:00"
generated_at: "2026-06-10T11:45:13.508680+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed raises $10.5M in private placement; shifts focus to strategic partnering for neflamapimod in DLB

## Summary
- Gross proceeds ~$10.5M from sale of 3.36M units at $3.14 each; up to $21.7M additional if warrants fully exercised.
- Insiders including chair Joshua Boger, CEO John Alam trusts, and director Sylvie Grégoire purchased ~1.37M units.
- Net proceeds extend cash runway into Q2 2027; funds neflamapimod R&D and general corporate purposes.
- Strategic priority to find a partner for Phase 3 in dementia with Lewy bodies after FDA/EMA alignment on registration path.
- Near-term milestones: nfvPPA Phase 2a clinical data Q1 2027; ALS Phase 2a trial initiation Q4 2026.

## SEC filing metadata
- accession: 0001437749-26-020080
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-06-10T11:40:43+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/0001437749-26-020080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/crvo20260610_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-020080
- JSON: https://secwatch.observer/filing/0001437749-26-020080.json
- Plain text: https://secwatch.observer/filing/0001437749-26-020080.txt

## Key facts
- Material Agreements
  CervoMed Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $10.5 million (effective 2026-06-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $10.5 million
  - Effective: 2026-06-09
  source text: On June 9, 2026, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 3,360,377 units (the “Units”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/0001437749-26-020080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.